Sensitivity Of Activated Murine Peritoneal-Macrophages To Photodynamic Killing With Benzoporphyrin Derivative

This study compared the ability of highly purified resting and activated DBA/2 mouse peritoneal macrophages to survive treatment with the photosensitizer benzoporphyrin derivative (BPD, verteporfin) and light. Culture of macrophages with recombinant murine interferon-gamma (rIFN-gamma, 100 U/mL) for 72 h imparted a phenotypic and functional activation by dramatically increasing cell surface expression of major histocompatibility complex Class II (Ia) molecules and the formation of nitric oxide. The rIFN-gamma-activated macrophages were significantly (P < 0.05) more sensitive (lethal dose to cause a 50% reduction in cell survival, LD(50) = 14.4 +/- 1.1 ng/mL) to photodynamic killing with BPD and light (10 J/cm(2)) than cells (LD(50) = 18.2 +/- 2.0 ng/mL) cultured in medium alone. In contrast, macrophages treated with different concentrations of bacterial lipopolysaccharide (LPS) were as resistant or more resistant to photodynamic killing than cells cultured in medium alone. No cytotoxic effect of BPD was detected in cultures containing the drug but protected from light. Comparable amounts of BPD were taken up in vitro by unactivated and rIFN-gamma-activated macrophages, as detected by flow cytometric analysis. However, cells cultured with LPS (10 mu g/mL) took up more BPD than macrophages cultured in medium alone or with rIFN-gamma. The DBA/2 P815 mastocytoma cells took up greater amounts of the drug and were subsequently more vulnerable to treatment with BPD and light (LD(50) = 6.9 ng/mL) than macrophages cultured under any condition. The explanation for the increased vulnerability of rIFN-gamma-activated macrophages and the greater resistance of LPS-activated macrophages, relative to medium-cultured macrophages, to photodynamic killing with BPD is uncertain. However, the increased susceptibility of macrophages, activated with the immunomodulatory cytokine IFN-gamma, to treatment with BPD and light might indicate how photodynamic therapy could interfere with the development of experimental autoimmune disease, conditions in which activated macrophages are known to be involved.